The Latest Progress In Early Chemotherapy Of Hormone Sensitivity Prostate Cancer

Since 1941,androgen deprivation therapy has been the primary treatment for metastatic hormone-sensitive prostate cancer,but after 24 to 36 months endocrine rheraphy,the disease will eventually progress to hormone resistant prostate cancer.docetaxel combined with prednisone is the first-line therapy for metastatic castration resistant prostate.In recent years,the early intervention of docetaxel in hormone sensitivity prostate cancer have became a research hot spot,There are three studies have showed clinical benefit,and would lead to a paradigm shift in primary pharmacotherapy for metastatic hormone-sensitive prostate cancer.In this paper,I will combine with recent clinical research results and related guidelines to review the research progress of docetaxel in hormone sensitive prostate cancer.